1, N 6 -Ethano-2‘-deoxyadenosine ( 1 ) is one of the adducts formed during DNA reaction with the antitumor agent, 1,3-bis(2-chloroethyl)nitrosourea (BCNU), and was synthesized and incorporated into a site-specific deoxyoligonucleotide for the first time. The product 6-chloropurine-2‘-deoxyriboside ( 11 ) was prepared in high yield by the reaction of 2‘-deoxyinosine ( 6 ) with SOCl 2, which then was derivatized to give compound 12 using tert -butyldimethylsilyl chloride, which was then reacted with 2-hydroxyethylamine to produce compound 13 in 86% yield. Reaction of 13 with (PhO) 3 P + MeI - in DMF gave the cyclized 1, N 6 -ethano derivative 10 in 67% yield. Desilylation of 10 with triethylamine trihydrofluoride in THF gave 1, N 6 -ethano-dA ( 1 ) in 91% yield. Tritylation of compound 1 with DMT + BF 4 - gave the 5‘- O -DMT product 14 in 62% yield, which then was phosphitylated with 2-cyanoethyl N, N -diisopropylchlorophosphoramidite, which yielded a 1:1 mixture of the diastereoisomers 15 in 71% yield. This fully protected compound 15 was incorporated site-specifically into a 25-mer oligonucleotide. The coupling efficiency of ethano-dA phosphoramidite was 93%. Enzymatic hydrolysis and analysis by HPLC confirmed the incorporation of ethano-dA and base composition of the DNA oligomer. The latter is now under investigation for its biochemical and physical properties.
No takes yet. Share an insight, caveat, or question.
Maruenda et al. (1998) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: